Trial Profile
A phase 2 study of ZK219477 [sagopilone] (ZK-EPO) in patients with breast cancer and brain metastases.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 18 Mar 2013
Price :
$35
*
At a glance
- Drugs Sagopilone (Primary)
- Indications Advanced breast cancer; Cancer metastases
- Focus Therapeutic Use
- 11 Mar 2013 Actual end date Jan 2012 added as reported by ClinicalTrials.gov.
- 17 Dec 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 10 Sep 2009 Planned number of patients changed from 37 to 49 as reported by ClinicalTrials.gov.